A New Immunotherapy Treatment Option for Advanced Cervical Cancer
THE FDA APPROVED THE IMMUNE CHECKPOINT INHIBITOR PEMBROLIZUMAB IN COMBINATION AND AS A SINGLE AGENT FOR ADVANCED CERVICAL CANCER...
Progress Against Cancer
THE FDA APPROVED THE IMMUNE CHECKPOINT INHIBITOR PEMBROLIZUMAB IN COMBINATION AND AS A SINGLE AGENT FOR ADVANCED CERVICAL CANCER...
THE FDA APPROVED A NEW TYPE OF CANCER INHIBITOR FOR CERTAIN PATIENTS WITH A HIGH RISK OF RECURRENCE The...
THE FDA APPROVED THE FIRST CAR-T CELL THERAPY FOR CERTAIN PATIENTS WITH this aggressive form of LEUKEMIA The U.S....
THE FDA GRANTED ACCELERATED APPROVAL TO A NEW THERAPY FOR ADVANCED CERVICAL CANCER The U.S. Food and Drug Administration...
The FDA approved a tyrosine kinase inhibitor for certain patients with thyroid cancer. The U.S. Food and Drug Administration...
The FDA granted accelerated approval to a new targeted therapeutic and companion diagnostic test for certain adult patients with...
THE FDA GRANTED ACCELERATED APPROVAL TO ZANUBRUTINIB FOR CERTAIN ADULTS WITH MARGINAL ZONE LYMPHOMA The U.S. Food and Drug...
The FDA approved zanubrutinib, a tyrosine kinase inhibitor, for this form of non-Hodgkin lymphoma. The U.S. Food and Drug...
The U.S. FDA approved a molecularly targeted therapeutic to treat certain patients with cholangiocarcinoma. The U.S. Food and Drug...
The U.S. FDA granted accelerated approval to an immunotherapeutic and a companion diagnostic test to treat certain cancer patients...